65,437 trials
Pain
Primary: Changes in QST Measures in Response to Acupuncture or Gabapentin at Visit 1, Visit 4 and Visit 7 for CS, WS, HP, CP (CS: Cold Sensation; WS: Warm Sensation; HP: Heat…
Diabetes Mellitus
Primary: Percentage of Time Spent in HCL After CGM Sensor Meets Initial Validation Criteria — 91 percentage of time
Primary Sjögren's Syndrome
Primary: Change in ESSDAI Total Score — -3.77; -5.54; 11.52; 13.12 score on a scale
Myopia · Refractive Errors
Primary: Variability of the Refractive Predicatibility — -0.22 Diopters
Major Depressive Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS) Score Change — -21.7; -14.6 summed total scores — p==0.040
Risk Reduction Behavior · Health Behavior · Sexual Behavior
Primary: Number of Participants With Risky Sexual Behavior Measured for 1 Year — 143; 155; 162 Participants
Osteoarthritis, Knee
Primary: Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT — -5.4; -5.2 score on a scale — p=0.6742
Sickle Cell Disease (SCD)
Primary: Pharmacokinetic (PK): AUCd15 and AUCtau of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) Patients — 13100; 20800 hr*μg/mL
Sickle Cell Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs) — 2; 2; 4; 2 Participants
Medication-Induced Dyskinesia
Primary: Number of Participants With Adverse Events (AEs) — 16; 7; 0; 1 Participants
Type 1 Diabetes
Primary: Percent Time in Range (Baseline) — 40.6 percentage of CGM wear time — p=0.70
HIV/AIDS · Hypertension · Hyperlipidemias
Primary: Systolic Blood Pressure — 134.9; 134.9; 129.9; 136.3 model estimated mmhg
Pain Management · Vaginal Delivery
Primary: Patient Reported Average Pain Score — 1.37; 1.06; 2.03; 2.41 units on a scale — p==0.25
Nail Diseases
Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
Heart Failure Acute
Primary: Total Natriuresis After 24 Hours — 409; 345 mmol